$5m takes prostate disorder co closer to market
This article was originally published in Clinica
Executive Summary
MD Venture Partners, an Irvine, California-based healthcare VC, has invested $5m in ProstimRx, a company developing a medical device for treating prostate-related disorders. Hendersonville, Tennessee-based ProstimRx said it intends to use the funds to gain US FDA clearance and CE-marking for its technology. The ProstimRx procedure has been used in over 10,000 clinical cases to treat prostatitis, benign prostate hypertrophy, erectile dysfunction and other diseases linked to the prostate problems.